References1. Freier D, Zeiner K, Biesen R, et al. Bone mineral density and fracture frequencies in patients with psoriasis or psoriasis arthritis. Presented at: EULAR 2018; June 13-16, 2018; Amsterdam, The Netherlands. Abstract AB0915.2. Camacho-Sanchez MR, Lopez-Medina C, Bautista-Aguilar L, et al. Evaluation of cardiovascular risk factors among patients with psoriasis, psoriatic arthritis and peripheral spondyloarthritis. Presented at: EULAR 2018; June 13-16, 2018; Amsterdam, The Netherlands. Abstract THU0297.
Two studies recently presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, The Netherlands, focus on the risks of osteoporosis and cardiovascular disease in patients on the psoriatic arthritis/psoriasis spectrum.
Freier and colleagues from Germany found that glucocorticoid dose had no impact on bone mineral density, which was comparable to that of persons without psoriasis or psoriatic arthritis.1 Camacho-Sanchez and fellow researchers in Spain showed that the prevalence of cardiovascular risk factors is similar between all types of psoriasis diseases but is higher than in the general population.2
Scroll through the slides for the details of the studies and the take-home points for clinicians.
BMD, bone mineral density; PsA, psoriatic arthritis.
BMD, bone mineral density; GC, glucocorticoid; Rh-GIOP, Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis.
The prevalence of osteopenia and osteoporosis was higher in patients with psoriasis than in those with psoriatic arthritis (70% vs 45%) without reaching statistical significance. The mean body mass index (BMI) was 28.9 (± 5.9), and a higher BMI correlated positively with BMD (P = .01).
PsA, psoriatic arthritis; SpA, spondyloarthritis.
The presence of arthritis or psoriasis was not associated with the development of type 2 diabetes mellitus and dyslipidemia.
